Skip to main content
IO Biotech, Inc. logo

IO Biotech, Inc. — Investor Relations & Filings

Ticker · IOBT ISIN · US4497781090 US Manufacturing
Filings indexed 265 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country US United States of America
Listing US IOBT

About IO Biotech, Inc.

https://www.iobiotech.com/

IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory therapeutic cancer vaccines. The company's proprietary T-win technology platform is engineered to create dual-action vaccines that activate the patient's T cells to simultaneously target and eliminate both cancer cells and immune-suppressive cells within the tumor microenvironment. These off-the-shelf therapies are intended to improve outcomes for patients with various solid tumors. The lead product candidate, Cylembio® (IO102-IO103), is being evaluated in clinical trials for melanoma and other cancers, while additional pipeline candidates are in preclinical development.

Recent filings

Filing Released Lang Actions
8-K - IO Biotech, Inc. (0001865494) (Filer)
Regulatory Filings
2026-03-31 English
8-K Filing
Regulatory Filings
2026-02-13 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-06 English
8-K Filing
Regulatory Filings
2026-01-30 English
Major Shareholding Notification 2026
Major Shareholding Notification
2026-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.